glp·helper
glphelper.com/semaglutide/tennessee/maryville
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Maryville, TN

Verified Semaglutide providers in Maryville, TN. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
25
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Tennessee
25 of 25 shown

Find a Semaglutide provider in Tennessee.

Every entry is checked against the NPI registry and the Tennessee medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Tennessee city · /semaglutide/tennessee/{city}
§ 03Getting Semaglutide in Maryville
25 providers · Maryville, TN

How to get Semaglutide in Maryville.

25 GLP-1 prescribers and 6 local resource types are on record for Maryville, plus 3 nearby towns in the directory.

Prescribers in Maryville
25 prescribers
25 GLP-1 prescribers in Maryville, most listed as Family Medicine (14), Internal Medicine (6) and Internal Medicine, Endocrinology, Diabetes & Metabolism (4). Any Tennessee-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Knoxville (42 providers), Oak Ridge (26 providers) and Morristown (24 providers).
Around the prescription in Maryville
6 listed nearby
13 dietitians, 6 gyms, 6 fitness clubs, 4 trainers, 6 physiotherapists and 4 places to move are on record near Maryville.
Medicaid (weight loss)
Covered
As of April 2026, Tennessee Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Tennessee’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Maryville

Maryville, Tennessee has a population of 31,907 people. The adult obesity rate in Maryville is an age-adjusted estimate of 35.9%, 1.7 percentage points below the Tennessee state rate of 37.6%. Diagnosed diabetes reaches 10.5% of adults in Maryville. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 23.8% of adults in Maryville.

of Maryville adults have obesity
35.9%
diagnosed diabetes
10.5%
no regular physical activity
23.8%

Age-adjusted estimates for Maryville, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight losswhat happens after GLP-1s stop
§ 05Support around Semaglutide in Maryville
6 fitness clubs

The prescription is one part. Here is the rest, in Maryville.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Maryville, TN, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Neighborhood Barre Maryville
FITNESS
5.0 on Google · 17 reviews
212 W Harper Ave
Website
Planet Fitness
GYM
4.6 on Google · 1234 reviews
541 N Foothills Plaza Dr
Website
National Fitness
GYM
4.0 on Google · 507 reviews
1644 W Broadway Ave
Website
Get Fit Maryville
TRAINING
5.0 on Google · 116 reviews
911 E Broadway Ave
Website
Orangetheory Fitness
GYM
4.8 on Google · 76 reviews
1012 Alcoa Mkt St
Website
Quick Fitness 24/7
FITNESS
4.7 on Google · 63 reviews
1010 William Blount Dr
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Kimberly Chism, R.D
RD
Registered dietitian
1123 Mercer Dr
Call 813-713-3891NPI 1295069631
Linda Colvin
RD
Registered dietitian
131 Montgomery Ln
Call 865-304-3070NPI 1265809396
Courtney Howell-Johnson, RD, LDN
RD
Registered dietitian
3217 Willow Branch Cir
Call 865-363-0092NPI 1528687597
Maggie Johnson, RD
RD
Registered dietitian
1450 Dowell Springs Blvd
Call 865-637-8812NPI 1104309301
Heather Pierce, RD
RD
Registered dietitian
405 Bmh Physicians Office Bldg
Call 865-238-6430NPI 1790863678
Megan Prather, RDN, LDN
RD
Registered dietitian
3028 Old Niles Ferry Rd
Call 980-855-1865NPI 1720896525
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in Tennessee

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in Tennessee

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]